Cite
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.
MLA
Nishizato, Yohei, et al. “Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) Genes: Consequences for Pravastatin Pharmacokinetics.” Clinical Pharmacology and Therapeutics, vol. 73, no. 6, June 2003, pp. 554–65. EBSCOhost, https://doi.org/10.1016/S0009-9236(03)00060-2.
APA
Nishizato, Y., Ieiri, I., Suzuki, H., Kimura, M., Kawabata, K., Hirota, T., Takane, H., Irie, S., Kusuhara, H., Urasaki, Y., Urae, A., Higuchi, S., Otsubo, K., & Sugiyama, Y. (2003). Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clinical Pharmacology and Therapeutics, 73(6), 554–565. https://doi.org/10.1016/S0009-9236(03)00060-2
Chicago
Nishizato, Yohei, Ichiro Ieiri, Hiroshi Suzuki, Miyuki Kimura, Kiyoshi Kawabata, Takeshi Hirota, Hiroshi Takane, et al. 2003. “Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) Genes: Consequences for Pravastatin Pharmacokinetics.” Clinical Pharmacology and Therapeutics 73 (6): 554–65. doi:10.1016/S0009-9236(03)00060-2.